Mr. Kim has served as the Company’s Chief Corporate Officer since March 2025. He has over 20 years of experience in the biopharmaceutical industry as a senior executive and an investment banker. In 2024, Mr. Kim was the Chief Financial Officer at TriArm Therapeutics, a private biotechnology company specializing in CAR-T therapies. Prior to his role at TriArm, Mr. Kim was a Managing Director at Stifel, Raymond James, Cantor Fitzgerald, and Jefferies, focused on biopharmaceutical coverage. He has advised on and executed over 100 transactions, totaling approximately $13 billion in mezzanine, public equity, and debt financings, as well as $12 billion in business development and M&A transactions.